logo
  

Sysco Q1 Adj. Profit Beats View, But Revenues Miss - Quick Facts

Sysco Corp. (SYY), a foodservice distribution company, reported first-quarter net earnings of $453.78 million or $0.87 per share, up from $431.04 million or $0.81 per share in the year-ago period.

Excluding items, adjusted earnings for the quarter were $0.98 per share, compared to $0.91 per share last year.

Net sales for the quarter rose 0.6 percent to $15.30 billion from $15.22 billion in the year-ago period.

On average, analysts polled by Thomson Reuters expected the company to report earnings of $0.97 per share for the quarter on revenues of $15.51 billion. Analysts' estimates typically exclude special items.

"We saw improved financial results in the first quarter with adjusted operating income growth that was in line with our expectations, as we remain focused on accelerating local case growth and maintaining our strong track record of expense management," said Tom Bené, Sysco's chairman, president and chief executive officer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT